background

Press Releases

Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies

US FDA approved IND submitted by Pharmazz, Inc. to initiate a phase III clinical trial of centhaquine in patients with hypovolemic shock
FD Aapproved

WILLOWBROOK, Ill., Sept. 29, 2021 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, is pleased to announce that its Phase III clinical study of the drug candidate, centhaquine, has been approved by the US FDA for the treatment of hypovolemic shock. The Phase III clinical study will be a multi-centric, double-blind, placebo-controlled to be conducted on 430 patients randomly assigned equally to both arms with 28-day mortality as the primary endpoint. Pharmazz is expected to begin enrollment towards the end of 2021 or the beginning of 2022.

Sovateltide (PMZ-1620), a first-in-class investigational product, shows promise to slow down the progression of Alzheimer's disease in patients
sovateltide

WILLOWBROOK, Ill., June 10, 2021 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care. The Company is developing sovateltide for Alzheimer's disease.Drugs approved for Alzheimer's disease treatment include the cholinesterase inhibitors donepezil, rivastigmine, and galantamine, and the N-methyl-D-aspartate antagonist memantine. Recently, aducanumab a monoclonal antibody that targets β-amyloid was approved by the US FDA. Although aducanumab improves Clinical Dementia Rating, there is an unmet need for therapies that halt or slow the progression of Alzheimer's disease.

Centhaquine Improved Shock Index, ARDS, MODS, Reduced Blood Lactate Levels, And 8.8% Absolute Reduction In 28-Day All-Cause Mortality
centhaquine

WILLOWBROOK, Ill., June 10, 2021 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care. The Company is developing sovateltide for Alzheimer's disease.Drugs approved for Alzheimer's disease treatment include the cholinesterase inhibitors donepezil, rivastigmine, and galantamine, and the N-methyl-D-aspartate antagonist memantine. Recently, aducanumab a monoclonal antibody that targets β-amyloid was approved by the US FDA. Although aducanumab improves Clinical Dementia Rating, there is an unmet need for therapies that halt or slow the progression of Alzheimer's disease.

Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial
biopharmaceutical

WILLOWBROOK, Ill., May 10, 2021 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care. The Company is marketing Centhaquine Citrate, with the brand name Lyfaquin® to health care professionals in India.Pharmazz is pleased to announce the peer-reviewed publication of the manuscript titled "Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial."

Lyfaquin®, a resuscitative agent marketed in India, restores renal blood flow and protects tissue damage after hemorrhagic shock-induced acute kidney injury (AKI)
biopharmaceutical

May 3, 2021, - WILLOWBROOK, Ill., May 3, 2021 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care. The Company is marketing Centhaquine Citrate, with the brand name Lyfaquin® to health care professionals in India. Pharmazz is pleased to announce the peer-reviewed publication of the manuscript titled "Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia." The manuscript is published in Frontier in Pharmacology and is available https://doi.org/10.3389/fphar.2021.616253. Lyfaquin® increased renal blood flow, augmented hypoxia response, decreased tissue damage, and apoptosis following hemorrhagic shock-induced acute kidney injury (AKI) in the rat.

Lyfaquin®, a first-in-class resuscitative agent for patients with excessive blood loss, to be launched in India
biopharmaceutical

July 20, 2020, - WILLOWBROOK, Ill., July 20, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced that it has successfully received marketing authorization and is preparing to launch Lyfaquin® (centhaquine), a novel resuscitative agent indicated for the treatment of patients with hypovolemic shock as a frontline adjuvant to standard of care. The company plans to make Lyfaquin® available to patients by the middle of September 2020.

Marketing authorization received for Lyfaquin™ (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency
hypovolemic shock

May 14, 2020, - WILLOWBROOK, Ill., May 14, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it has received marketing authorization of centhaquine, a first-in-class drug, to manage patients with hypovolemic shock from the Indian regulatory agency. Centhaquine is likely to be a transformational therapy for hypovolemic shock because it ameliorates key drivers of mortality.

Sovateltide significantly (p=0.0157) improved clinical outcome (modified Rankin Scale) in patients with acute cerebral ischemic stroke when compared to standard of care
Sovateltide

Apr 27, 2020, - WILLOWBROOK, Ill., April 27, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that sovateltide, an endothelin-B receptor agonist, significantly (p=0.0157; two-tailed unpaired t-test; t=2.476; df=70) improved modified Rankin Scale (mRS) of acute cerebral ischemic stroke patients when compared to patients receiving the best standard of care. These results are based on an interim 30-day analysis of multicentric, randomized, blinded, controlled efficacy clinical trials (NCT04046484; NCT04047563) in acute ischemic stroke patients.

Centhaquine can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, acute respiratory distress syndrome (ARDS), multiple organ dysfunction score (MODS) and mortality in coronavirus disease 2019 (COVID-19) patients
Centhaquine

Apr 09, 2020, - WILLOWBROOK, Ill., April 9, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that centhaquine, a drug in final stage of development, can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome (ARDS), reduce multiple organ dysfunction score (MODS) and decrease mortality in patients with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Dosing of first patient in phase 3 pivotal study of sovateltide (PMZ-1620), a first-in-class investigational product, for acute cerebral ischemic stroke
pivotal study

Nov. 23, 2019, - WILLOWBROOK, Ill., Nov. 23, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced the initiation of dosing in its pivotal, phase 3 clinical trial evaluating sovateltide for the treatment of acute cerebral ischemic stroke

Pharmazz submits application for marketing authorization of centhaquine (PMZ-2010), a first-in-class investigational product, for patients with hypovolemic shock
centhaquine

Oct. 28, 2019, - WILLOWBROOK, Ill., Oct. 28, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it successfully submitted Application for Marketing Authorization of centhaquine to the Central Drugs Standard Control Organization (CDSCO)...

Sovateltide (PMZ-1620), an Endothelin-B receptor Agonist, has the potential to be a first-in-class neuronal progenitor cell therapeutics
Agonist

Sept. 30, 2019, - WILLOWBROOK, Ill., Sept. 30, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it made 5 presentations at the Sixteenth International Conference on Endothelin held in Kobe...

PMZ-1620, an Endothelin-B Agonist, enters Phase III Trial in Patients with Cerebral Ischemic Stroke
Endothelin-B

July 18, 2019, - WILLOWBROOK, Ill., July 18, 2019 /PRNewswire/ -- Pharmazz, Inc., today announced that it has received permission to initiate a prospective, multicentric, randomized, double-blind, parallel, phase III clinical study to assess efficacy of PMZ-1620 along with standard treatment in patients of acute ischemic stroke in India...

Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019
Ongoing

Feb. 07, 2019, - NAPERVILLE, Ill., Feb. 7, 2019 /PRNewswire/ -- Pharmazz, Inc., today announced that data from the Phase 2 clinical study in patients with acute cerebral ischemic stroke, were presented in the late breaking Multicenter, Ongoing Clinical Trials Posters II (Board CTP27) session at the International Stroke Conference 2019 in Honolulu, Hawaii February 6-8, 2019...

Phase 2 Results on Efficacy of PMZ-2010 (Centhaquin) in Patients with Hypovolemic Shock Presented at AHA Scientific Sessions 2018
Efficacy

Nov. 12, 2018, - NAPERVILLE, Ill., Nov. 12, 2018 /PRNewswire/ -- Pharmazz, Inc., today announced that data from the Phase 2 clinical study in patients with hypovolemic shock, were presented in the Drug Discovery-Heart Failure Oral Abstracts Session II at the American Heart Association Scientific Sessions in Chicago November 12, 2018.